|
Market Closed -
Nasdaq
16:00:00 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 19.27 USD | +3.44% |
|
+12.10% | +12.20% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Biotechnology | - | - | - | - | - | |||||
Total Assets | 419M | 591M | 378M | 277M | 326M | |||||
Interest Expense | -19.67M | -22.7M | -30.84M | -24.68M | -13.31M | |||||
Income Tax Expense | - | - | - | - | 2.01M | |||||
CAPEX | -277K | -113K | -426K | -165K | -65K | |||||
EBT | -192M | -182M | -175M | -183M | -2.8M | |||||
D&A | 1.39M | 952K | 920K | 950K | 964K | |||||
Operating Income | -174M | -163M | -165M | -169M | -123M | |||||
Net Income | 194M | 47.42M | -118M | -157M | -3.35M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | - | - | - | - | - | |||||
Total Assets | 419M | 591M | 378M | 277M | 326M | |||||
Interest Expense | -19.67M | -22.7M | -30.84M | -24.68M | -13.31M | |||||
Income Tax Expense | - | - | - | - | 2.01M | |||||
D&A | 1.39M | 952K | 920K | 950K | 964K | |||||
CAPEX | -277K | -113K | -426K | -165K | -65K | |||||
Net Income | 194M | 47.42M | -118M | -157M | -3.35M | |||||
EBT | -192M | -182M | -175M | -183M | -2.8M | |||||
Operating Income | -174M | -163M | -165M | -169M | -123M |
- Stock Market
- Stocks
- OMER Stock
- Financials Omeros Corporation
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
